CombinatoRx to Present at the Noble Financial Sixth Annual Equity Conference
May 27 2010 - 7:30AM
Business Wire
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that
Mark Corrigan, President and CEO is scheduled to present at the
Noble Financial Sixth Annual Equity Conference at 5:00pm EDT on
June 7, 2010, at the Hard Rock Hotel in Hollywood, Florida.
Interested parties may access a live webcast of the presentation by
visiting the CombinatoRx website at www.combinatorx.com or through
the Noble Financial website www.ontrack10.com, or
www.nobleresearch.com. The webcast will be archived on the
CombinatoRx website following the event.
About CombinatoRx
CombinatoRx, Incorporated (CRXX) develops novel drug candidates
with a focus on the treatment of pain and inflammation. The company
applies its combination drug discovery capabilities and its
selective ion-channel modulation platform to generate innovative
therapeutics. To learn more about CombinatoRx, please visit
www.combinatorx.com.
About Noble Financial
Noble Financial Capital Markets was established in 1984 and is
an equity research driven, full-service investment banking boutique
focused on small-cap, emerging growth companies. The company has
offices in New York, Boston, New Jersey, St Louis and Boca
Raton.
Forward-Looking Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
concerning CombinatoRx, the CombinatoRx selective ion channel
modulation platform, its combination drug discovery technology, and
business plans. These forward-looking statements about future
expectations, plans, objectives and prospects of CombinatoRx may be
identified by words like "believe," "expect," "may," "will,"
"should," "seek," or “could” and similar expressions and involve
significant risks, uncertainties and assumptions, including risks
related to the sale and marketing of Exalgo by Covidien, risks
related to the development and regulatory approval of CombinatoRx’s
product candidates, the unproven nature of the CombinatoRx drug
discovery technologies, the ability of the Company or its
collaboration partners to initiate and successfully complete
clinical trials of its product candidates, the Company's ability to
obtain additional financing or funding for its research and
development and those other risks that can be found in the "Risk
Factors" section of CombinatoRx's Annual Report on Form 10-K, on
file with the Securities and Exchange Commission and the other
reports that CombinatoRx periodically files with the Securities and
Exchange Commission. Actual results may differ materially from
those CombinatoRx contemplated by these forward-looking statements.
These forward looking statements reflect management’s current views
and CombinatoRx does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
(c) 2010 CombinatoRx, Incorporated. All rights reserved.
Combinatorx (NASDAQ:CRXX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Combinatorx (NASDAQ:CRXX)
Historical Stock Chart
From Apr 2023 to Apr 2024